DUGiDocsAn integrin-targeted photoactivatable Pt(iv) complex as a selective anticancer pro-drug: Synthesis and photoactivation studies
dc.contributor.author
dc.date.accessioned
2016-03-18T10:40:28Z
dc.date.available
2016-03-18T10:40:28Z
dc.date.issued
2015
dc.identifier.issn
1359-7345
dc.identifier.uri
dc.description.abstract
A new anticancer agent based on the conjugation of a photoactivatable Pt(iv) pro-drug to a cyclic RGD-containing peptide is described. Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing α<inf>V</inf>β<inf>3</inf> integrin compared to control DU-145 human prostate carcinoma cells
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Royal Society of Chemistry (RSC)
dc.relation.isformatof
Reproducció digital del document publicat a: http://dx.doi.org/10.1039/C5CC03180J
dc.relation.ispartof
© Chemical Communications, 2015, vol. 51, p. 9169-9172
dc.relation.ispartofseries
Articles publicats (D-B)
dc.rights
Attribution 3.0 Spain
dc.rights.uri
dc.subject
dc.title
An integrin-targeted photoactivatable Pt(iv) complex as a selective anticancer pro-drug: Synthesis and photoactivation studies
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.embargo.terms
Cap
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.identifier.eissn
1364-548X